<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02443064</url>
  </required_header>
  <id_info>
    <org_study_id>XYH-88</org_study_id>
    <secondary_id>zju-vancamycin</secondary_id>
    <nct_id>NCT02443064</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin</brief_title>
  <official_title>Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin in the Treatment of Methicillin-resistant Staphylococcus Aureus（MRSA） Blood Stream Infection (Septicemia) and Endocarditis in Chinese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou General Hospital of Guangzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial Hospital of TCM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Drug resistance of G+ cocci is a severe healthcare problem. According to the Ministry of&#xD;
           Health National Antimicrobial Resistant Investigation Net (mohnarin) surveillance&#xD;
           report, the isolation rate of MRSA is some 60% in China. MRSA infection has become a&#xD;
           serious clinical problem;&#xD;
&#xD;
        2. Vancomycin is a bactericidal glycopeptide antibiotic which inhibits bacterial growth by&#xD;
           hindering the synthesis of cell wall in bacteria. It exerts strong antibiotic effect to&#xD;
           Gram+ bacteria. It is indicated for serious staphylococcus infections especially MRSA&#xD;
           infection and has become the gold standard agent in MRSA treatment;&#xD;
&#xD;
        3. Vancomycin is a time-dependent antibiotic, its clinical and microbiological efficacy is&#xD;
           related to area under curve（ AUC）/minimum inhibitory concentration （MIC ）(AUIC). Cmin at&#xD;
           steady state is an surrogate parameter of AUIC, which is closely associated to the&#xD;
           efficacy;&#xD;
&#xD;
        4. AUIC &gt;400 and Cmin between 15~20 mg/L are recommended for effective vancomycin treatment&#xD;
           by Infectious Diseases Society of America （IDSA） although it is still disputable;&#xD;
&#xD;
        5. Due to the absence of PK/PD study on vancomycin in China, administration of vancomycin&#xD;
           is performed in reference to the recommendation of IDSA. Its suitability to Chinese&#xD;
           patients is still to be clarified;&#xD;
&#xD;
        6. Plasma concentrations of vancomycin vary significantly between population and&#xD;
           individuals. Factors such as large-volume fluid infusion, hypoproteinemia and renal&#xD;
           clearance, etc. will influence the distribution and excretion of vancomycin, resulting&#xD;
           in different plasma concentrations between individuals. Results of PK studies differ&#xD;
           greatly between China and abroad. Administration based on the AUIC or Cmin recommended&#xD;
           by IDSA would not be suitable to Chinese patients. Given the definite long-term benefit&#xD;
           of vancomycin treatment, the AUIC or Cmin suitable to Chinese patients must be&#xD;
           identified by clinical study.&#xD;
&#xD;
        7. The PK/PD study on vancomycin in the treatment to MRSA septicemia and endocarditis is of&#xD;
           great significance for more reasonable use and improved therapeutic efficacy of MRSA&#xD;
           infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:&#xD;
&#xD;
      A multi-center, non-controlled, open-labeled observational study&#xD;
&#xD;
      Research objectives&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To explore the PK/PD target value (AUIC) of vancomycin in the treatment of MRSA septicemia&#xD;
      and endocarditis in Chinese patients.&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
      To detect the therapeutic efficacy and safety of vancomycin in the treatment of MRSA&#xD;
      septicemia and endocarditis in Chinese patients.&#xD;
&#xD;
      To exam the relationship between the Cmin of vancomycin and its efficacy in the treatment to&#xD;
      MRSA septicemia and endocarditis.&#xD;
&#xD;
      To explore the relationship between MRSA molecular type and vancomycin therapeutic efficacy&#xD;
&#xD;
      Medicine and administration&#xD;
&#xD;
      Drug:&#xD;
&#xD;
      Vancomycin&#xD;
&#xD;
      Dosing:&#xD;
&#xD;
      15~20 mg/kg, IV, q 12~8h (or 1 g, IV, q12~8h) for adult patient with normal renal function;&#xD;
      Dosage should be adjusted by blood creatinine clearance in patients with impaired renal&#xD;
      function; Administration route： 1~2 h/ dosing, IV&#xD;
&#xD;
      Drug combination:&#xD;
&#xD;
      Drug combination is not recommended for patients with simple MRSA infection; Rifampicin can&#xD;
      be combined in case of MRSA artificial valve endocarditis; Anti-G- antibacterial agents can&#xD;
      be combined in case of concurrent G- bacterial infections.&#xD;
&#xD;
      Duration:&#xD;
&#xD;
      Septicemia: 2~4 weeks Endocarditis: 6~8 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC/MIC of vancomycin in each patient</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with negative blood culture at the end of treatment</measure>
    <time_frame>Participants will be followed during vancomycin treatment and in average of 4 weeks after vancomycin treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Participants will be followed during vancomycin treatment and in average of 4 weeks after vancomycin treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants survival</measure>
    <time_frame>Participants will be followed during vancomycin treatment and in average of 4 weeks after vancomycin treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Blood Stream Infections</condition>
  <condition>Endocarditis</condition>
  <condition>MRSA</condition>
  <arm_group>
    <arm_group_label>MRSA blood stream infection patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:Vancomycin&#xD;
Dosing:&#xD;
15-20mg/kg, IV,q 12~8h (or 1 g, IV, q12~8h) for adult patient with normal renal function; Dosage should be adjusted by blood creatinine clearance in patients with impaired renal function; Administration route： 1~2 h/ dosing, IV&#xD;
Drug combination:&#xD;
Drug combination is not recommended for patients with simple MRSA infection; Rifampicin can be combined in case of MRSA artificial valve endocarditis; Anti-G- antibacterial agents can be combined in case of concurrent G- bacterial infections.&#xD;
Duration:&#xD;
Septicemia: 2~4 weeks Endocarditis: 6~8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Vancomycin was administered for Chinese patients with MRSA blood stream infection and endocarditis Pharmacokinetics: 5 blood samples collected at steady state for the determination of plasma concentrations for population pharmacokinetics (PPK) analysis.&#xD;
Microbiology: blood cultures for MRSA isolation, MIC of vancomycin against MRSA; molecular typing will be analyzed on bacterial strains including heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate Staphylococcus aureus （VISA); Safety evaluation: hepatic and renal function, blood routine test, and so on.</description>
    <arm_group_label>MRSA blood stream infection patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years, male or female;&#xD;
&#xD;
          2. diagnosed as MRSA septicemia or endocarditis; Septicemia clinical manifestations of&#xD;
             infection; MRSA infection confirmed by blood culture; Endocarditis: diagnosed&#xD;
             according to modified Duke Criteria&#xD;
&#xD;
          3. no therapy with effective anti-MRSA drugs 72 hours prior to the study; Effective&#xD;
             anti-MRSA drugs used in China include: vancomycin, norvancomycin, teicoplanin,&#xD;
             linezolid, daptomycin, tigecycline, and fusidic acid.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. those being allergic to glycopeptides antibiotics;&#xD;
&#xD;
          2. those with osteomyelitis, central nervous system infection or other septic migrations&#xD;
             (except for endocarditis);&#xD;
&#xD;
          3. patients with catheter-related bloodstream infection who cannot withdraw catheter;&#xD;
&#xD;
          4. those during chemotherapy for cancer or leukemia;&#xD;
&#xD;
          5. those with agranulocytosis;&#xD;
&#xD;
          6. those with HIV infection;&#xD;
&#xD;
          7. women in pregnancy or lactation;&#xD;
&#xD;
          8. patients receiving vancomycin for less than 72 hours;&#xD;
&#xD;
          9. patients participating in any other clinical trial in 3 months prior to the study (not&#xD;
             limited to trials for antibiotics)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong-hong Xiao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yong-hong Xiao, MD</last_name>
    <phone>+86-571-87236421</phone>
    <email>xiao-yonghong@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yong-Hong Xiao</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong-Hong Xiao, MD</last_name>
      <phone>+86-571-87236421</phone>
      <email>xiao-yonghong@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011 Apr 15;52(8):975-81. doi: 10.1093/cid/cir124.</citation>
    <PMID>21460309</PMID>
  </reference>
  <reference>
    <citation>Brown J, Brown K, Forrest A. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemother. 2012 Feb;56(2):634-8. doi: 10.1128/AAC.05609-11. Epub 2011 Nov 28.</citation>
    <PMID>22123681</PMID>
  </reference>
  <reference>
    <citation>Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011 Feb 1;52(3):285-92. doi: 10.1093/cid/cir034.</citation>
    <PMID>21217178</PMID>
  </reference>
  <reference>
    <citation>Anonymous. Expert consensus on the use of vancomycin(2011). Chin J of New Drug &amp; Regimen. 2011，30（8）：561-56</citation>
  </reference>
  <results_reference>
    <citation>1.Xiao YH, et al. 2010 report of Mohnarin. Chin J Nosocomial Infect. 2012, 22(22):4946-4952</citation>
  </results_reference>
  <results_reference>
    <citation>Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43(13):925-42.</citation>
    <PMID>15509186</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>November 23, 2014</study_first_submitted>
  <study_first_submitted_qc>May 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <last_update_submitted>May 8, 2015</last_update_submitted>
  <last_update_submitted_qc>May 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Yong-Hong Xiao</investigator_full_name>
    <investigator_title>Vice Director, China State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou.</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics/pharmacodynamics</keyword>
  <keyword>vancomycin</keyword>
  <keyword>blood stream infections</keyword>
  <keyword>Chinese patients</keyword>
  <keyword>MRSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

